Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Baxalta
Baxalta
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Finance
Shareholders approve Shire's merger with Baxalta
Will create 'the leading global biotechnology company in rare diseases and other highly specialised conditions', the firms say
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Latest EU drug approvals span range of health issues
Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Finance
Shire to buy Baxalta for US$32bn
Creating a global leader in rare diseases
Research & Development
Baxalta agrees $1.6bn cancer deal with Symphogen
Will advance novel therapeutics against six targets
Research & Development
Baxalta opens Global Innovation Centre in Cambridge, MA, US
Will serve as the firm's HQ for R&D, oncology, biosimilars and business development
Finance
Shire makes hostile all-stock US$30bn bid for Baxalta
To create the leading global biotechnology company focused on rare diseases
Research & Development
Baxalta appoints Jacopo Leonardi as EVP and President Immunology
Biopharmaceutical firm specialises in developing and manufacturing plasma-based therapies for rare diseases
Subscribe now